| P/E (FY) | 114.9 | Sales (TTM) | $769.1M |
| Earnings (TTM) | $47.3M | ROE | 15.01% |
| Net Margin | 13.09% | ROIC | 8.30% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | −1.95% | Sales Growth 3Y | 23.74% |
Corcept Therapeutics is a biopharmaceutical company discovering and developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. Its marketed product Korlym treats hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome. The pipeline includes selective cortisol modulators such as relacorilant, miricorilant for metabolic steatohepatitis, nenocorilant, and dazucorilant.
| Market Cap | $10.11B | Trading Days | 5292 |
| 52W High | 97.63 |
| 52W Low | 28.66 |
| % Off High | −3.52% |
| YTD | 170.66% | 1Y | 36.21% |
| 3Y | 271.56% | 5Y | 361.72% |
| 10Y | 1507.34% | Since incept. (ann.) | 14.06% |
| Ann. Volatility (1Y) | 78.73% | Ann. Volatility (3Y) | 90.24% |
| Sharpe (1Y) | 0.88 | Sharpe (3Y) | 0.88 |
| Max Drawdown (1Y) | −64.40% | Max Drawdown (3Y) | −71.85% |
| Beta (3Y, vs SPY) | 0.34 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | $10.21B | — |
| SMMT | Summit Therapeutics Inc. | $10.01B | — |
| CYTK | CYTOKINETICS INC | $9.89B | — |
| IONS | IONIS PHARMACEUTICALS INC | $9.14B | — |
| NUVL | Nuvalent, Inc. | $9.01B | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | — |
| PTGX | Protagonist Therapeutics, Inc | $8.80B | — |
| SYRE | Spyre Therapeutics, Inc. | $8.68B | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $12.00B | 34.5 |
| AXSM | Axsome Therapeutics, Inc. | $12.05B | — |
| ALKS | Alkermes plc. | $8.47B |
| 35.3 |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.08B | — |
